Cipla Ltd


BSE: 500087 | NSE: CIPLA | ISIN: INE059A01026 
Market Cap: [Rs.Cr.] 24,890 | Face Value: [Rs.] 2
Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

 Discuss this stock

Board Meet

10-May-12 
Quarterly Results 
13-Feb-12 
Cipla Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 13, 2012, inter alia, to consider Unaudited Financial Results for third quarter ended December 31, 2011 (Q3). 
14-Nov-11 
Cipla Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 14, 2011, inter alia, to consider Unaudited Financial Results for second quarter ended September 30, 2011. Cipla Ltd has informed BSE that: 1. Appointment of an Additional Director: The Board of Directors at its meeting held on November 14, 2011, have appointed Dr. Ranjan Pai as an Additional Director on the Board of Directors of the Company. 2. Appointment of Chief Financial Officer: As a part of broad-basing the Company's organisational structure, Mr. V. S. Mani has been appointed as the Chief Financial Officer of the Company. (As Per BSE Announcement Website dated on 14.11.2011) 
05-Aug-11 
Cipla Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on August 05, 2011, inter-alia to consider Unaudited Financial Results for first quarter ended 30 June, 2011. (Q1) 
29-Jun-11 
Cipla Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on June 29, 2011, inter alia, to consider the Annual Audited Accounts for the year ended March 31, 2011 and Recommendation of Dividend, if any. Cipla Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 29, 2011, inter alia, has recommended payment of final dividend of Rs. 2 per equity share (face value Rs. 2) for the year 2010-2011 amounting to Rs. 160.58 Crores. In September 2010, the Company paid an interim dividend of 80 paise per equity share (face value of Rs. 2) for the year 2010-2011. (As Per BSE Announcement Website dated on 29.06.2011) 

AGM

25-Aug-11
AGM 25.08.2011 Cipla Ltd has informed BSE that the members at the 75th Annual General Meeting (AGM) of the Company held on August 25, 2011, inter alia, have passed the following resolutions: 1. Balance Sheet as at March 31, 2011, the Profit and Loss Account for the year ended on that date together with the schedules annexed thereto as well as the reports of the Board of Directors and Auditors thereon were adopted. 2. Interim Dividend paid at the rate of 40% on 80,29,21,357 Equity Shares of Rs. 2/- each for the financial year ended March 31, 2011 was confirmed. Final Dividend at the rate of 100% on 80,29,21,357 Equity Shares of Rs 21- each for the financial year ended March 31, 2011 was declared. 3. Mr. M. R. Raghavan has been re-appointed as Director of the Company. 4. Mr. Pankaj Patel has been re-appointed as Director of the Company. 5. M/s. V. Sankar Aiyar & Co., Chartered Accountants together with M/s. R. G. N. Price & Co., Chartered Accountants have been re-appointed as Joint Statutory Auditors of the Company. 6. Appointment of Mr. S. Radhakrishnan as Director of the Company and ratification of his appointment as Whole-time Director with effect from November 12, 2010 was approved. 7. Appointment of Mrs. Samina Vaziralli as a member of management team of the Company was approved. 
25-Aug-10
Cipla Limited has informed the Exchange that the Annual General Meeting of the Company will be held on August 25, 2010. Cipla Ltd has informed BSE that at the 74th Annual General Meeting of the Members of the Company held on August 25, 2010, all resolutions as mentioned in the Notice were passed with requisite majority. A brief summary of the resolutions passed at the Annual General Meeting are as under: 1. Balance Sheet as at March 31, 2010, the Profit and Loss Account for the year ended on that date together with the schedules annexed thereto as well as the reports of the Board of Directors and Auditors thereon were adopted. 2. Dividend at the rate of 100% on 80,29,21,357 Equity Shares of Rs. 2/- each for the financial year ended March 31, 2010 was declared. 3. Dr. H. R. Manchanda has been re-appointed as Director of the Company 4. Mr. Ramesh Shroff has been re-appointed as Director of the Company. 5. M/s. R.G.N. Price & Co., Chartered Accountants together with M/s. V. Sankar Aiyar & Co., Chartered Accountants have been re-appointed as Joint Statutory Auditors of the Company. 6. Special Resolution for appointment of Mr. Kamil Hamied as a member of Management team of the Company was approved. (As Per BSE Announcement Dated on 27.08.2010) 
26-Aug-09
Cipla Ltd. has informed the Exchange that the Annual General Meeting of the members of the Company will be held on August 26, 2009. Cipla Ltd has informed BSE that the members at the Annual General Meeting (AGM) of the Company held on August 26, 2009, inter alia, have accorded to the following: 1. Adoption of the Balance Sheet of the Company as at March 31, 2009, the Profit and Loss Account for the year ended on that date together with schedules annexed thereto as well as the reports of the Board of Directors and Auditors. 2. Declaration of Dividend at the rate of 100% on 77,72,91,357 Equity Shares of Rs. 2/- each, absorbing an amount of Rs. 155,45,82,714/- for the financial year ended on March 31, 2009. 3. Re-appointment of Mr. S. A. A. Pinto & Mr. V. C. Kotwal as Directors of the Company. 4. Appointment of M/s. R. G. N. Price & Co., Chartered Accountants, Mumbai (the retiring Auditors) together with M/s. V. Sankar Aiyar & Co., Chartered Accountants, Mumbai, appointed as Joint Statutory Auditors of the Company to hold office from the conclusion of this Annual General Meeting until the conclusion of the next Annual General Meeting of the Company, on remuneration, terms & conditions. 5. Authority to the Board to create, offer, issue and allot, in one or more tranches, in domestic and/or international markets, equity shares or warrants simultaneously with non-convertible debentures or foreign currency convertible bonds ('FCCBs') convertible into equity shares of the Company or American Depository Receipts or Global Depository Receipts represented by underlying equity shares of the Company or other securities exchangeable or convertible into equity shares of the Company ('Securities'), for an amount upto Rs. 1500 crore (Rupees One Thousand Five Hundred Crore only), inclusive of such premium, as may be finalised by the Board, at such price being not less than the price determined in accordance with the applicable Guidelines / Regulations issued by SEBI or the Ministry of Finance or the RBI and such issue and allotment to be made on such terms and conditions as may be decided by the Board at the time of issue or allotment of the Securities. (As Per BSE Announcement Website dated on 28.08.2009) 
28-Aug-08
Cipla Ltd. has informed the Exchange that the Annual General Meeting of the Company will be held on August 28, 2008. Cipla Ltd has informed BSE that that the members at the Annual General Meeting (AGM) of the Company held on August 28, 2008, inter alia, have passed the following resolutions: 1. Adoption the Balance Sheet of the Company as at March 31, 2008, the Profit and Loss Account for the year ended on that date together with schedules annexed thereto. 2. Declaration of Dividend at the rate of 100% on Equity Shares of Rs 2/- each for the year ended March 31, 2008. 3. Re-appointment of Dr. M R Raghavan as a Director of the Company. 4. Re-appointment of M/s. R S Bharucha & Co., Chartered Accountants together with M/s. R G N Price & Co., Chartered Accountants as Auditors of the Company to hold office from the conclusion of this Annual General Meeting until the conclusion of the next Annual General Meeting of the Company on remuneration, terms & conditions. 5. Appointment of Mr. Pankaj Patel as a Director of the Company, liable to retire by rotation. 6. Re-appointment of Dr. Y K Hamied as Managing Director of the Company for a further period of five years commencing on August 01, 2008 and ending July 31, 2013, on remuneration, terms & conditions. 7. Re-appointment of Dr. M K Hamied as Joint Managing Director of the Company for a further period of five years commencing on August 01, 2008 and ending July 31, 2013, on remuneration, terms & conditions. (As Per BSE Announcement Website Dated on 29.08.2008) 
24-Aug-07
Cipla Ltd. has informed the Exchange that the Annual General Meeting of the Company will be held on August 24, 2007. Cipla Ltd has informed BSE that that the members at the Annual General Meeting (AGM) of the Company held on August 24, 2007, inter alia, have unanimously passed the following resolutions: 1. Adoption of the Directors Report together with the audited Balance Sheet as on March 31, 2007 and the Profit and Loss Accounts for Account for the year ended on that date and the Auditors Report thereon. 2. Declaration of Dividend at the rate of 100% on Equity Shares of Rs 2/- each for the year ended March 31, 2007. 3. Re-appointment of Dr. H R Manchanda & Mr. Ramesh Shroff as Directors of the Company. 4. Appointment of M/s. R S Bharucha & Co., Chartered Accountants together with M/s. R G N Price & Co., Chartered Accountants as Joint Statutory Auditors of the Company to hold office from the conclusion of this Annual General Meeting until the conclusion of the next Annual General Meeting of the Company on remuneration, terms & conditions. (As per BSE Announcement Website Dated on 27/08/2007) 

EGM

21-Mar-06
Cipla Ltd. has submitted to the Exchange a copy of the Minutes of the deemed EGM of the Company held on March 21, 2006.  
21-Apr-04
EGM 21/04/2004 To approve the sub-division in the face value of equity shares of the company from Rs 10/- to Rs 2/-. Cipla Ltd. has informed the Exchange that an EGM of the Company will be held on April 21,2004 to transact the following business; (1) To obtain consent of the shareholders for the issue and allotment in the aggregate of Rs. 1700 [One thousand Seven Hundred only] equity shares of Rs. 10/- each in the Company credited as fully paid to the equity Shareholders of Oncocare India Private Limited, Medule Pharma Private Limited, Medex Specialities Private Limited, Lancet Pharma Private Limited, Inhaled Technologies Private Limited and Nebumed Pharma Private Limited [whether such members are members of the Company or not] pursuant to and subject to the terms and conditions of the Scheme of Arrangement between Oncocare India Private Limited, Medule Pharma Private Limited, Medex Specialities Private Limited, Lancet Pharma Private Limited, Inhaled Technologies Private Limited and Nebumed Pharma Private Limited and the company and its respective members, provided that the aforesaid allotment shall be subject to the Scheme of Arrangement being approved by the High Court. Further, in the event of the above resolution being carried through with requisite majority, 8500 equity shares of the face value of Rs. 2/- each be issued to the persons as aforesaid instead of 1700 equity shares of Rs. 10/- each. (2) To reduce the nominal value of equity shares of the Company by sub-dividing the equity shares to make it more affordable to the retailinvestor. This will enable the small investors to enter the market. Therefore, it is proposed that the nominal value of equity shares of the Company be reduced from Rs.10/- each to Rs. 2/- each. (3) Consequent to the sub-division of shares, it is necessary to alter the capital clause of the Memorandum and Articles of Association. (As perNSE Bulletin dated on 31/03/2004) The Company has informed that at the Extra Ordinary General Meeting of the members of the Company held on April 21,2004, all the resolutions including resolution for sub-division in facevalue of Equity Shares from Rs 10/-to Rs 2/- were passed with requisite majority. (As per BSE Bulletin dated on 23/04/2004) 

Peer Comparison

Company Market Cap
(Rs. in Cr.)
P/E (TTM)
(x)
P/BV (TTM)
(x)
EV/EBIDTA
(x)
ROE
(%)
ROCE
(%)
D/E
(x)
Sun Pharma.Inds. 59,024.02 36.91 8.84 29.33 22.3 23.3 0.01
Dr Reddy's Labs 28,898.96 31.67 4.30 22.23 15.0 15.2 0.17
Cipla 24,889.90 22.14 3.32 18.79 15.4 17.9 0.04
Ranbaxy Labs. 22,222.51 17.79 11.55 0.00 0.0 0.0 1.22
Cadila Health. 15,284.86 23.25 6.00 21.79 32.9 27.5 0.31
Glenmark Pharma. 9,637.92 36.32 4.41 24.56 11.3 11.9 0.51
Wockhardt 8,617.31 29.96 71.71 39.85 0.0 0.0 3.18
Piramal Health 7,302.32 55.83 0.66 0.33 4.2 6.1 0.07
Torrent Pharma. 5,414.83 14.93 4.15 11.43 29.5 25.9 0.55
Biocon 4,322.00 16.91 2.06 11.21 26.2 26.8 0.10
Ipca Labs. 4,270.28 15.69 4.05 10.26 26.5 25.1 0.51
Strides Arcolab 3,982.81 61.55 2.94 16.20 5.1 5.7 0.97
Aurobindo Pharma 3,357.84 10.43 1.31 8.01 26.5 19.7 0.95
Matrix Labs. 3,273.19 8.13 2.00 0.00 28.9 27.4 0.52
Fres.Kabi Onco. 2,187.12 83.79 4.04 16.45 9.5 10.8 0.58

Futures & Options Quote

 
Expiry Date
309.10 1.50  [0.5]%
Instrument: FUTSTK
Expiry Date: 31 May 2012
Open Price: 307.50
Average Price: 309.43
No. of Contracts Traded: 122,000
Open Interest: 2,223,000
Underlying: CIPLA
Market Lot: 1000
Previous Close: 310.60
Day’s High | Low: 310.95 | 307.50
Turnover (Cr.): 3.78
Open Int. Change: 41,000.00 (1.9% )
View detailed F& O quotes >>

Key Information

Key Executives:

Y K Hamied , Chairman & Managing Director 

M K Hamied , Joint Managing Director 

S Radhakrishnan , Whole-time Director 

V C Kotwal , Director 


Company Head Office / Quarters:
Mumbai Central,
,
Mumbai,
Maharashtra-400008
Phone : 91-22-23025272/23095521/23082891
Fax : 91-22-23008101/23070013/23070393
E-mail : cosecretary@cipla.com
Web : http://www.cipla.com
Registrars:
Karvy Computershare Pvt Ltd
Plot No 17-24
Vittal Rao Nagar
Madhapur
Hyderabad-500081

Calendar

May-2012
M T W T F S S
21 22 23 24 25 26 27
IPO
listNo IPO today
Economic Events
list U. of Michigan Confidence
list Italian Hourly Wages (MoM)
Results
list Reliance Infra. | Crompton Greaves | ITC | Guj Fluorochem